Komori
Kissei Pharmaceutical (4547) · InitiativeAdvanced

Expansion of Other Businesses through Medical Software and Next-Generation Technologies

First written in FY2017. 3 of 6 entries say "Advanced", first in FY2020. Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019AdvancedFY2020 – FY20262017: 120172018: 120182019: 120192020: 120202021: 020212022: 020222023: 020232024: 120242025: 020252026: 12026
Same theme, other companies

1 other company's latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Revenue in the Information Services business was ¥14,237 million, up 63.0% year on year, due to orders received for projects related to the GIGA School policy promoted by the Ministry of Education, Culture, Sports, Science and Technology.」

    Revenue in the Information Services business rose 63.0% through orders for projects related to the GIGA School policy, turning the expansion of the Other businesses into actual results.
  2. FY2024-Q3AdvancedAnnual report

    「The acquisition of this business is consistent with Kissei Comtec Co., Ltd.’s medium- to long-term business strategy, including developing the market for lifecycle management of information-related equipment and establishing a used-equipment sales business. It will also complement the markets, customer base, and service offerings of its rental business, and is expected to generate synergies for further expansion of that business.」

    Kissei Comtec acquired Neplus Co., Ltd.’s network equipment rental and sales business through an absorption-type company split effective 1 December 2023. The acquisition consideration was ¥750 million, and provisional goodwill was ¥342 million, giving concrete form to the expansion of the rental business and the development of the lifecycle management market.
  3. FY2020AdvancedAnnual report

    「In the Information Services business, the Company is promoting system development to address social issues in areas such as healthcare and nursing care, the development of packaged software for various fields, and the adoption of next-generation technologies. Total R&D expenses were ¥148 million.」

    To expand the Other businesses, the Company has specified measures involving systems addressing social issues in healthcare, nursing care and other areas, packaged software, and the adoption of next-generation technologies.
  4. FY2019RestatedAnnual report

    「In the Other businesses, the Company is laying the groundwork for expansion, including through active investment in advanced information technology research related to software development.」

    The Company has reaffirmed the creation of a foundation for expanding the Other businesses through investment in advanced information technology research.
  5. FY2018RestatedAnnual report

    「In the Other businesses, the Company is laying the groundwork for expansion, including through active investment in advanced information technology research related to software development.」

    The Company has reaffirmed the creation of a foundation for expanding the Other businesses through investment in advanced information technology research.
  6. FY2017First statedAnnual report

    「In the Other businesses, the Company is laying the groundwork for expansion, including through active investment in advanced information technology research related to software development.」

    For the Other businesses, the Company has newly described the creation of a foundation for business expansion through investment in advanced information technology research.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 3 of its 6 moves.

333222★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages3×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval3×
  4. 3Stable dividends and profit allocation in line with earnings3×
  5. 4Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market2×
  6. 5Promoting overseas expansion and stabilizing the overseas earnings base2×
  7. 6Share Buybacks and Cancellations as Flexible Capital Policy Measures2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Expansion of Other Businesses through Medical Software and Next-Generation Technologies | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori